China Universal Asset Management Co. Ltd. Acquires 1,174 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

China Universal Asset Management Co. Ltd. boosted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 10.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,634 shares of the company’s stock after acquiring an additional 1,174 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Structure Therapeutics were worth $343,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares during the last quarter. Assetmark Inc. lifted its stake in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares during the period. FNY Investment Advisers LLC bought a new position in Structure Therapeutics during the fourth quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the period. Finally, Dearborn Partners LLC bought a new stake in shares of Structure Therapeutics in the 3rd quarter valued at about $202,000. 91.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GPCR shares. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Price Performance

GPCR opened at $29.97 on Monday. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -40.50 and a beta of -2.78. The business’s 50-day moving average price is $29.65 and its two-hundred day moving average price is $35.20. Structure Therapeutics Inc. has a 1 year low of $23.50 and a 1 year high of $62.74.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.